In a study, osthole downregulated n6-methyladenosine-modified TGM2 to exert its additive effect with methotrexate and suppress the proliferation, migration, and invasion of RA-FLSs by attenuating NF-κB signaling pathway, resulting in the suppression of RA progression (179). Here, TGM2 is linked to rheumatoid arthritis.